Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 4

Fospropofol disodium injection for the sedation of patients undergoing colonoscopy

Authors Benjamin E Levitzky, John J Vargo

Published 8 August 2008 Volume 2008:4(4) Pages 733—738

DOI https://doi.org/10.2147/TCRM.S3091

Review by Single-blind

Peer reviewer comments 2

Benjamin E Levitzky1, John J Vargo2

1Department of Gastroenterology and Hepatology, 2Section of Therapeutic and Hepatobiliary Endoscopy, Department of Gastroenterology and Hepatology, Cleveland Clinic Foundation, Cleveland, Ohio, USA

Abstract: Sedation plays a central role in making colonoscopy tolerable for patients and feasible for the endoscopist to perform. The array of agents used for endoscopic sedation continues to evolve. Fospropofol (FP), a prodrug of propofol with a slower pharmacokinetic profi le, is currently under evaluation for use during endoscopic procedures. Preliminary data suggests that FP dosed at 6.5 mg/kg is well tolerated by most patients with perineal paresthesias being the most commonly experienced adverse effect. This article will examine the current literature on the use of FP for the sedation of patients undergoing colonoscopy, highlighting the pharmacokinetics, pharmacodynamics, risks, and common adverse events associated with the novel sedative/hypnotic.

Keywords: fospropofol, Aquavan, propofol, sedation, colonoscopy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Vinflunine in the treatment of bladder cancer

Mark Bachner, Maria De Santis

Therapeutics and Clinical Risk Management 2008, 4:1243-1253

Published Date: 5 December 2008

Levofloxacin in the treatment of complicated urinary tract infections and acute pyelonephritis

Jessina C McGregor, George P Allen, David T Bearden

Therapeutics and Clinical Risk Management 2008, 4:843-853

Published Date: 10 October 2008

A systematic approach of tracking and reporting medication errors at a tertiary care university hospital, Karachi, Pakistan

Khurshid Khowaja, Rozmin Nizar, Rashida J Merchant, Jacqueline Dias, Irma Bustamante-Gavino, Amina Malik

Therapeutics and Clinical Risk Management 2008, 4:673-679

Published Date: 8 August 2008

Combating HIV resistance – focus on darunavir

Cécile L Tremblay

Therapeutics and Clinical Risk Management 2008, 4:759-765

Published Date: 8 August 2008

Sevelamer carbonate in the treatment of hyperphosphatemia in patients with chronic kidney disease on hemodialysis

Vincenzo Savica, Domenico Santoro, Paolo Monardo, Agostino Mallamace, Guido Bellinghieri

Therapeutics and Clinical Risk Management 2008, 4:821-826

Published Date: 8 August 2008

Early ischemic CT changes before thrombolysis: The influence of age and diabetes mellitus

Lars Thomassen, Ulrike Waje-Andreassen, Halvor Naess

Therapeutics and Clinical Risk Management 2008, 4:699-703

Published Date: 8 August 2008

A review of nasal polyposis

Jonathan Ray Newton, Kim Wong Ah-See

Therapeutics and Clinical Risk Management 2008, 4:507-512

Published Date: 11 April 2008